Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

In reversal, Georgia joins $26 billion U.S. opioid settlement

Published 01/07/2022, 09:01 AM
Updated 01/07/2022, 01:16 PM
© Reuters. FILE PHOTO: Tablets of the opioid-based Hydrocodone at a pharmacy in Portsmouth, Ohio, June 21, 2017.  REUTERS/Bryan Woolston

By Nate Raymond

(Reuters) - The state of Georgia has decided to join a proposed $26 billion nationwide settlement resolving lawsuits alleging that three large drug distributors and drugmaker Johnson & Johnson (NYSE:JNJ) fueled the deadly U.S. opioid epidemic.

Friday's announcement by Georgia Attorney General Chris Carr marked the latest instance of a holdout state opting into the landmark agreements with J&J, McKesson Corp (NYSE:MCK), AmerisourceBergen (NYSE:ABC) Corp and Cardinal Health Inc (NYSE:CAH).

"We are confident that joining the settlement at this time will prove beneficial to our state, our citizens and our communities, as we continue our fight to end this epidemic and address the widespread damage it has caused," Carr said.

AmerisourceBergen said it was "pleased to see the increased commitment to participation in the global settlement process." J&J referred to an earlier statement saying the deal supports state and local efforts address the epidemic.

More than 3,300 lawsuits, largely by state and local governments, are pending seeking to hold those and other companies responsible for an opioid abuse crisis that led to hundreds of thousands of overdose deaths.

Under a proposal unveiled in July, the distributors and J&J agreed to pay up to $21 billion and $5 billion, respectively.

How much the companies ultimately must pay and how much outstanding litigation they will face depends on state and local government participation.

Settlement supporters recently extended to Jan. 26 a deadline for cities and counties in states that backed the proposal to opt-in to the deals, citing the potential for more states to join.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Nevada did so Tuesday, and New Mexico in December backed the distributors' deal. Five states are left for the distributors to contend with, including the state of Washington, which has taken them to trial.

Six states have not settled with J&J, including New Hampshire, where a judge on Friday cleared the way https://tmsnrt.rs/3q0dQWl for the state to take J&J to trial on Feb. 1 for creating a public nuisance.

Latest comments

Need to target the subscribing doctors and pharmacies that failed to monitor the usage. All you needed to do was contact the pharmacy for a refill, they would call to get the prescription update from the doctors office with no verification of need.
good. out fn standing. f the sacklers for good...should publicly hang them all.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.